Condition: Breast Cancer · Sponsor: Institute of Cancer Research, United Kingdom
This is a study aimed at testing a commonly available and inexpensive chemical (hydrogen peroxide) for efficacy in sensitising large cancerous lumps in the breast to a standard course of radiotherapy in patients with locally advanced or recurrent breast cancer. Laboratory research and initial clinical trials in Japan suggest that 4 to 6 injections of a radiation sensitiser ('KORTUC') based on very dilute (0.5%) hydrogen peroxide injected into cancers under local anaesthetic twice a week during radiotherapy greatly increases the effectiveness of standard doses of radiotherapy alone. The side effects are limited to mild/moderate discomfort at the injection site for up to 24 hours reported by Japanese breast cancer patients in whom this treatment has been tested. Complete tumour shrinkage in 70/71 (98%) primary breast cancers up to 5 cm diameter have been reported by Japanese collaborators.
This description comes directly from the study's public registry record.
Lone Gothard · +44(0)2086613460 · lone.gothard@icr.ac.uk
Justine Hughes · +44(0)2086613273 · justine.hughes@icr.ac.uk
Always discuss trial participation with your own doctor first.
| Regional Cancer Centre (RCC) | Trivandrum, Kerala, India | Recruiting |
| Christian Medical Centre | Vellore, Tamil Nadu, India | Recruiting |
| Tata Medical Centre | Kolkata, West Bengal, India | Recruiting |
| Tata Memorial Centre | Mumbai, India | Recruiting |
| Royal Cornwall Hospitals NHS Trust | Truro, Cornwall, United Kingdom | Recruiting |
| Beatson West of Scotland Cancer Centre | Glasgow, Scotland, United Kingdom | Recruiting |
| Cambridge University Hospitals NHS Foundation Trust | Cambridge, United Kingdom | Recruiting |
| The Christie NHS Foundation Trust | Manchester, United Kingdom | Recruiting |
| University Hospitals of North Midlands NHS Trust | Stoke-on-Trent, United Kingdom | Recruiting |
| The Royal Marsden NHS Foundation Trust | Sutton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03946202